Despite its association with peripheral lymphopenia, and specifically CD4 + lymphopenia, the original landmark clinical trials demonstrated similar overall incidences of infection between participants treated with fingolimod, and control groups [21], [25]. The gene discussed is CD4; the disease is infection.